AAPL   274.75 (+0.45%)
FB   190.16 (+0.22%)
MSFT   161.83 (+2.31%)
GOOGL   1,308.94 (-0.46%)
AMZN   1,868.00 (-0.87%)
CGC   18.11 (-1.79%)
NVDA   266.57 (+5.53%)
BABA   203.04 (-0.97%)
MU   52.02 (+2.85%)
TSLA   654.80 (-3.56%)
AMD   45.03 (+2.32%)
GILD   68.42 (-5.84%)
DIS   116.86 (-1.00%)
AAPL   274.75 (+0.45%)
FB   190.16 (+0.22%)
MSFT   161.83 (+2.31%)
GOOGL   1,308.94 (-0.46%)
AMZN   1,868.00 (-0.87%)
CGC   18.11 (-1.79%)
NVDA   266.57 (+5.53%)
BABA   203.04 (-0.97%)
MU   52.02 (+2.85%)
TSLA   654.80 (-3.56%)
AMD   45.03 (+2.32%)
GILD   68.42 (-5.84%)
DIS   116.86 (-1.00%)
AAPL   274.75 (+0.45%)
FB   190.16 (+0.22%)
MSFT   161.83 (+2.31%)
GOOGL   1,308.94 (-0.46%)
AMZN   1,868.00 (-0.87%)
CGC   18.11 (-1.79%)
NVDA   266.57 (+5.53%)
BABA   203.04 (-0.97%)
MU   52.02 (+2.85%)
TSLA   654.80 (-3.56%)
AMD   45.03 (+2.32%)
GILD   68.42 (-5.84%)
DIS   116.86 (-1.00%)
AAPL   274.75 (+0.45%)
FB   190.16 (+0.22%)
MSFT   161.83 (+2.31%)
GOOGL   1,308.94 (-0.46%)
AMZN   1,868.00 (-0.87%)
CGC   18.11 (-1.79%)
NVDA   266.57 (+5.53%)
BABA   203.04 (-0.97%)
MU   52.02 (+2.85%)
TSLA   654.80 (-3.56%)
AMD   45.03 (+2.32%)
GILD   68.42 (-5.84%)
DIS   116.86 (-1.00%)
Log in

NASDAQ:ONTX - Onconova Therapeutics Stock Price, Forecast & News

$0.43
-0.04 (-8.51 %)
(As of 02/28/2020 01:12 PM ET)
Today's Range
$0.40
Now: $0.43
$0.44
50-Day Range
$0.32
MA: $0.45
$0.60
52-Week Range
$0.10
Now: $0.43
$4.83
Volume428,993 shs
Average Volume25.52 million shs
Market Capitalization$59.65 million
P/E RatioN/A
Dividend YieldN/A
Beta2.68
Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONTX
CUSIPN/A
Phone267-759-3680

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.23 million
Book Value$0.95 per share

Profitability

Net Income$-20,570,000.00
Net Margins-967.77%

Miscellaneous

Employees25
Market Cap$59.65 million
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive ONTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ONTX and its competitors with MarketBeat's FREE daily newsletter.


Onconova Therapeutics (NASDAQ:ONTX) Frequently Asked Questions

What is Onconova Therapeutics' stock symbol?

Onconova Therapeutics trades on the NASDAQ under the ticker symbol "ONTX."

When did Onconova Therapeutics' stock split? How did Onconova Therapeutics' stock split work?

Shares of Onconova Therapeutics reverse split on the morning of Wednesday, September 26th 2018. The 1-15 reverse split was announced on Tuesday, September 25th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 25th 2018. An investor that had 100 shares of Onconova Therapeutics stock prior to the reverse split would have 7 shares after the split.

How were Onconova Therapeutics' earnings last quarter?

Onconova Therapeutics Inc (NASDAQ:ONTX) released its quarterly earnings data on Tuesday, August, 14th. The biopharmaceutical company reported ($1.05) EPS for the quarter, beating analysts' consensus estimates of ($1.20) by $0.15. The biopharmaceutical company had revenue of $0.49 million for the quarter, compared to analyst estimates of $0.52 million. Onconova Therapeutics had a negative return on equity of 872.01% and a negative net margin of 967.77%. View Onconova Therapeutics' Earnings History.

When is Onconova Therapeutics' next earnings date?

Onconova Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for Onconova Therapeutics.

What price target have analysts set for ONTX?

3 brokers have issued 1 year target prices for Onconova Therapeutics' stock. Their forecasts range from $1.30 to $25.00. On average, they expect Onconova Therapeutics' share price to reach $11.43 in the next year. This suggests a possible upside of 2,622.2% from the stock's current price. View Analyst Price Targets for Onconova Therapeutics.

What is the consensus analysts' recommendation for Onconova Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Onconova Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Onconova Therapeutics.

What are Wall Street analysts saying about Onconova Therapeutics stock?

Here are some recent quotes from research analysts about Onconova Therapeutics stock:
  • 1. According to Zacks Investment Research, "Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and developing small molecule drug candidates to treat cancer. The Company's products under different phases of development include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. " (1/29/2020)
  • 2. Maxim Group analysts commented, "Onconova announced that it has entered into a license agreement with HanX Biopharmaceuticals, Inc. (HanX, private) in China to develop and commercialize the company’s lead asset, rigosertib, which is currently in an ongoing pivotal P3 study (INSPIRE) for the treatment of higher-risk MDS (HR-MDS). This expands the collaboration with HanX, which already includes Onconova’s ON 1233000 (CDK 4/6 + ARK5 inhibitor)." (5/14/2019)

Has Onconova Therapeutics been receiving favorable news coverage?

Headlines about ONTX stock have been trending very negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Onconova Therapeutics earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Onconova Therapeutics.

Who are some of Onconova Therapeutics' key competitors?

What other stocks do shareholders of Onconova Therapeutics own?

Who are Onconova Therapeutics' key executives?

Onconova Therapeutics' management team includes the folowing people:
  • Dr. Steven M. Fruchtman, CEO, Pres & Director (Age 68)
  • Dr. E. Premkumar Reddy, Founder, Lead Scientific Advisor & Director (Age 75)
  • Dr. Manoj Maniar, Sr. VP of Product Devel. (Age 56)
  • Dr. Ramesh Kumar, Advisor (Age 63)
  • Mr. Mark Patrick Guerin, Chief Financial Officer (Age 50)

Who are Onconova Therapeutics' major shareholders?

Onconova Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (0.46%), Hillcrest Wealth Advisors NY LLC (0.18%) and UBS Group AG (0.07%). Company insiders that own Onconova Therapeutics stock include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, Henry S Bienen, James J Marino, Mark Patrick Guerin, Michael B Hoffman, Steven M Fruchtman and Tyndall Capital Partners L P. View Institutional Ownership Trends for Onconova Therapeutics.

Which major investors are buying Onconova Therapeutics stock?

ONTX stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Hillcrest Wealth Advisors NY LLC and UBS Group AG. Company insiders that have bought Onconova Therapeutics stock in the last two years include 683 Capital Management, Llc, Abraham N Oler, E Premkumar Reddy, Henry S Bienen, James J Marino, Mark Patrick Guerin and Steven M Fruchtman. View Insider Buying and Selling for Onconova Therapeutics.

How do I buy shares of Onconova Therapeutics?

Shares of ONTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Onconova Therapeutics' stock price today?

One share of ONTX stock can currently be purchased for approximately $0.42.

How big of a company is Onconova Therapeutics?

Onconova Therapeutics has a market capitalization of $58.27 million and generates $1.23 million in revenue each year. The biopharmaceutical company earns $-20,570,000.00 in net income (profit) each year or ($4.99) on an earnings per share basis. Onconova Therapeutics employs 25 workers across the globe.View Additional Information About Onconova Therapeutics.

What is Onconova Therapeutics' official website?

The official website for Onconova Therapeutics is http://www.onconova.com/.

How can I contact Onconova Therapeutics?

Onconova Therapeutics' mailing address is 375 PHEASANT RUN, NEWTOWN PA, 18940. The biopharmaceutical company can be reached via phone at 267-759-3680 or via email at [email protected]


MarketBeat Community Rating for Onconova Therapeutics (NASDAQ ONTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  322 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  595
MarketBeat's community ratings are surveys of what our community members think about Onconova Therapeutics and other stocks. Vote "Outperform" if you believe ONTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel